A US company, LumiThera Inc., based in Seattle, WA has reported summary trial data on photo-biomodulation, termed “LIGHTSITE III” study, conducted by a multi-centre clinical… Read More »US “LIGHTSITE III” clinical trial data on photo-biomodulation (PBT) treatment of dry AMD has reported vision improvement for 24 months.
Researchers led by clinical scientists at the Department of Clinical Neurosciences, University of Oxford, UK, has reported that, previously, there have been no disease-specific instruments… Read More »Two new RP/LCA-specific instruments have reported strong evidence for psychometric validity on measures with RP/LCA adults and caregivers of children.
Researchers at ProQR Therapeutics, an RNA company based in Leiden, the Netherlands, and with researchers at Radboud University Medical Center in Nijmegen, have reported results… Read More »Antisense oligonucleotide (AON) therapy for Stargardt disease type 1 (STGD1) provides a proof of concept with effective restoration of correct ABCA4 transcript splicing.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 19th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »May 19th, 2023 “EURETINA-Brief”© Issue No. 271
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***